LDE225 0.75% + Vehicle
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sporadic Superficial and Nodular Skin Basal Cell Carcinomas
Conditions
Sporadic Superficial and Nodular Skin Basal Cell Carcinomas
Trial Timeline
Dec 1, 2009 → Feb 1, 2011
NCT ID
NCT01033019About LDE225 0.75% + Vehicle
LDE225 0.75% + Vehicle is a phase 2 stage product being developed by Novartis for Sporadic Superficial and Nodular Skin Basal Cell Carcinomas. The current trial status is terminated. This product is registered under clinical trial identifier NCT01033019. Target conditions include Sporadic Superficial and Nodular Skin Basal Cell Carcinomas.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01033019 | Phase 2 | Terminated |
Competing Products
7 competing products in Sporadic Superficial and Nodular Skin Basal Cell Carcinomas
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bimagrumab + Placebo | Novartis | Phase 3 | 77 |
| BYM338 (Bimagrumab) | Novartis | Phase 2/3 | 65 |
| BYM338/bimagrumab + Placebo | Novartis | Phase 2/3 | 65 |
| Everolimus | Novartis | Phase 2 | 52 |
| BYM338 + Placebo | Novartis | Phase 2 | 52 |
| Vandetanib 300 mg | Sanofi | Pre-clinical | 22 |
| REGN2477+REGN1033 + Matching placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |